DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

B. Riley FBR Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $19

B. Riley FBR analyst Mayank Mamtani maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $25 to $19.

Benzinga · 03/13/2020 11:57

B. Riley FBR analyst Mayank Mamtani maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $25 to $19.